HTG Molecular Diagnostics (NASDAQ:HTGM) received a $6.00 price objective from analysts at HC Wainwright in a research report issued to clients and investors on Wednesday. The firm currently has a “buy” rating on the medical research company’s stock. HC Wainwright’s target price points to a potential upside of 50.38% from the company’s previous close.
Other research analysts also recently issued reports about the company. ValuEngine downgraded HTG Molecular Diagnostics from a “sell” rating to a “strong sell” rating in a research note on Tuesday, October 10th. Zacks Investment Research upgraded HTG Molecular Diagnostics from a “hold” rating to a “buy” rating and set a $2.50 target price for the company in a research report on Wednesday, November 15th. Finally, Canaccord Genuity increased their target price on HTG Molecular Diagnostics to $5.00 in a research report on Friday, January 5th. One research analyst has rated the stock with a sell rating, two have issued a hold rating and two have assigned a buy rating to the stock. HTG Molecular Diagnostics presently has a consensus rating of “Hold” and an average price target of $5.31.
Shares of HTG Molecular Diagnostics (NASDAQ:HTGM) traded down $0.17 during trading on Wednesday, reaching $3.99. 1,130,000 shares of the company were exchanged, compared to its average volume of 1,950,000. The company has a market cap of $43.81 and a PE ratio of -1.56. HTG Molecular Diagnostics has a 52 week low of $1.20 and a 52 week high of $13.25.
An institutional investor recently raised its position in HTG Molecular Diagnostics stock. Granahan Investment Management Inc. MA boosted its stake in shares of HTG Molecular Diagnostics Inc (NASDAQ:HTGM) by 488.3% during the 3rd quarter, according to its most recent 13F filing with the SEC. The firm owned 416,608 shares of the medical research company’s stock after buying an additional 345,798 shares during the period. Granahan Investment Management Inc. MA owned approximately 3.33% of HTG Molecular Diagnostics worth $708,000 at the end of the most recent quarter. Institutional investors own 13.60% of the company’s stock.
COPYRIGHT VIOLATION WARNING: This story was first published by American Banking News and is the sole property of of American Banking News. If you are viewing this story on another domain, it was illegally stolen and reposted in violation of U.S. & international trademark & copyright laws. The original version of this story can be viewed at https://www.americanbankingnews.com/2018/01/28/hc-wainwright-analysts-give-htg-molecular-diagnostics-htgm-a-6-00-price-target.html.
HTG Molecular Diagnostics Company Profile
HTG Molecular Diagnostics, Inc is a commercial-stage company that develops and markets a technology platform to facilitate the routine use of complex molecular profiling. The Company’s HTG Edge and HTG EdgeSeq platforms, consisting of instrumentation, consumables and software analytics, are used in sample profiling applications, including tumor profiling, molecular diagnostic testing and biomarker development.
Receive News & Ratings for HTG Molecular Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HTG Molecular Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.